Latest Pharma Insights
With Product Listing Off Menu, US FDA Supplement Programs’ Table Set For ‘Priority Deliverables’
Changing self-GRAS regulation, providing NDIN safety and identity guidance and modernizing supplement industry regulatory framework are on FDA’s “2026 priority deliverables,” but not requirement for public listing of all supplements available.
HBW Insight - January 29, 2026
Changing self-GRAS regulation, providing NDIN safety and identity guidance and modernizing supplement industry regulatory framework are on FDA’s “2026 priority deliverables,” but not requirement for public listing of all supplements available.
HBW Insight - January 29, 2026
New Medicare Negotiation List Spotlights Small Molecule Liability For Cancer Drugs
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Scrip - January 29, 2026
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Scrip - January 29, 2026
New Medicare Negotiation List Spotlights Small Molecule Liability For Cancer Drugs
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Scrip - January 29, 2026
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Scrip - January 29, 2026
New SAGA Colorectal Cancer Diagnostic Helps Predict Recurrence
Molecular diagnostics firm SAGA diagnostics has introduced a colorectal cancer test, which can detect even very low levels of cancer biomarkers. The test helps clinicians guide post-surgical treatment decisions.
Medtech Insight - January 28, 2026
Molecular diagnostics firm SAGA diagnostics has introduced a colorectal cancer test, which can detect even very low levels of cancer biomarkers. The test helps clinicians guide post-surgical treatment decisions.
Medtech Insight - January 28, 2026
GE HealthCare Sets Long-Cycle Expectations For Photon-Counting CT, PET Tracer Flyrcado
GE HealthCare CEO Arduini believes the imaging market is large enough to accommodate multiple players as adoption progresses, describing photon-counting CT as a long-cycle transition rather than a near-term shift.
Medtech Insight - January 28, 2026
GE HealthCare CEO Arduini believes the imaging market is large enough to accommodate multiple players as adoption progresses, describing photon-counting CT as a long-cycle transition rather than a near-term shift.
Medtech Insight - January 28, 2026
India’s Medtech Producers Say EU Trade Deal Marks New Era Of Healthcare Cooperation
Tariff elimination deal should bring lower acquisition costs, reduce procedure costs and mean wider deployment of advanced equipment for hospitals and diagnostic networks.
Medtech Insight - January 28, 2026
Tariff elimination deal should bring lower acquisition costs, reduce procedure costs and mean wider deployment of advanced equipment for hospitals and diagnostic networks.
Medtech Insight - January 28, 2026
How AI Will Transform Medtech Regulatory Affairs In The EU
AI promises to be the much-needed solution to the now overly complex field of EU medtech regulatory affairs. Will every stakeholder start using solutions such as Raiana?
Medtech Insight - January 28, 2026
AI promises to be the much-needed solution to the now overly complex field of EU medtech regulatory affairs. Will every stakeholder start using solutions such as Raiana?
Medtech Insight - January 28, 2026
Insulet Leans On Manufacturing Scale And Omnipod Launches As Patch Pump Competition Broadens
While several competitors are developing or launching patch pumps, Insulet CEO McEvoy described Omnipod as differentiated by both technology and manufacturing scale. She said the company has invested roughly $3bn across R&D and manufacturing.
Medtech Insight - January 28, 2026
While several competitors are developing or launching patch pumps, Insulet CEO McEvoy described Omnipod as differentiated by both technology and manufacturing scale. She said the company has invested roughly $3bn across R&D and manufacturing.
Medtech Insight - January 28, 2026
With Product Listing Off Menu, US FDA Supplement Programs’ Table Set For ‘Priority Deliverables’
Changing self-GRAS regulation, providing NDIN safety and identity guidance and modernizing supplement industry regulatory framework are on FDA’s “2026 priority deliverables,” but not requirement for public listing of all supplements available.
HBW Insight - January 29, 2026
Changing self-GRAS regulation, providing NDIN safety and identity guidance and modernizing supplement industry regulatory framework are on FDA’s “2026 priority deliverables,” but not requirement for public listing of all supplements available.
HBW Insight - January 29, 2026
Novartis’s Gal: US Risks Losing Out To China On Early Trials
The Swiss company’s strategy head, Ronny Gal, joins calls for improvement in US competitiveness, as McKinsey highlights competition from other Asian countries beyond China.
Generics Bulletin - January 28, 2026
The Swiss company’s strategy head, Ronny Gal, joins calls for improvement in US competitiveness, as McKinsey highlights competition from other Asian countries beyond China.
Generics Bulletin - January 28, 2026
As Novo Ups The Ante In Canada For Semaglutide, Can Dr Reddy’s Get To Market In Time?
Dr Reddy’s gears for semaglutide debut across markets, including India and Canada, where Novo Nordisk has second brands of the GLP-1 agonist potentially ready. Can the Indian group close out compliance queries from the Canadian regulator soon?
Generics Bulletin - January 28, 2026
Dr Reddy’s gears for semaglutide debut across markets, including India and Canada, where Novo Nordisk has second brands of the GLP-1 agonist potentially ready. Can the Indian group close out compliance queries from the Canadian regulator soon?
Generics Bulletin - January 28, 2026
Samsung Bioepis Reports First Quarterly Results Post Spin-Off
With the separation from its parent company now behind it, Samsung Bioepis celebrated its highest-ever annual revenues and outlined its vision of further growth.
Generics Bulletin - January 28, 2026
With the separation from its parent company now behind it, Samsung Bioepis celebrated its highest-ever annual revenues and outlined its vision of further growth.
Generics Bulletin - January 28, 2026
MS Pharma And Hetero Team Up On Biosimilars In Algeria
MS Pharma is continuing to capitalize on opportunities for localized manufacturing in the Middle East, with its latest deal with Hetero Biopharma covering five biosimilars.
Generics Bulletin - January 28, 2026
MS Pharma is continuing to capitalize on opportunities for localized manufacturing in the Middle East, with its latest deal with Hetero Biopharma covering five biosimilars.
Generics Bulletin - January 28, 2026
Anticipating 2026 ACC/AHA Guideline Updates That Will Impact The Cardiometabolic Landscape
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
In Vivo - January 27, 2026
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
In Vivo - January 27, 2026